Immune System Diseases

926 trials 377 recruiting

Filter these 926 trials by phase, country and sponsor.

Open in Search →

Graves' disease is an immune system disorder that results in the overproduction of thyroid hormones. Ended

2024-512647-23-00 Grave's disease 4 2023-06-14
First-in-human study of SAR445611 in healthy adult participants Ended

2022-502923-23-00 Immune system diseases 1 2023-06-12
A Study to Evaluate the Efficacy and Safety of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa (S… Ended

2022-501753-36-00 Hidradenitis Suppurativa 5 2023-06-02
This is a study to evaluate dose-flexibility of Upadacitinib in Adult Subjects with Moderate to Severe Atopic Dermatitis Ended

2023-504869-23-00 Dermatitis atopic 11 2023-05-31
Study of M5049 in DM and PM Participants (NEPTUNIA) Ended

2022-501351-82-00 Dermatomyositis, Polymyositis 4 2023-05-23
A Phase 2 trial to evaluate the efficacy and safety of daxdilimab in participants with primary discoid lupus erythematosus. Ended

2023-509746-35-00 Primary Discoid Lupus Erythematosus 4 2023-05-16
A Phase 2 Proof of Concept Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of OMS90… Ended

2022-501190-39-01 Paroxysmal nocturnal hemoglobinuria 3 2023-05-15
Phase 3, 52-week Study Evaluating Rocatinlimab (AMG451)in Adolescent Subjects With Moderate-to-severe AD (ROCKET-ASTRO) Ended

2022-501586-50-00 Atopic Dermatitis 5 2023-05-15
Phase 3, Placebo-controlled, Double-blind Study Assessing Rocatinlimab (AMG 451) in Combination with Topical Corticosteroids and/or Topical … Ended

2022-501585-22-00 Atopic Dermatitis 5 2023-05-11
A Phase 3 open-label, controlled, randomised, multi-centre trial comparing imlifidase and standard-of-care with standard-of-care alone in th… Ended

2022-500121-33-01 Anti-GBM antibody disease (Goodpasture disease) 5 2023-05-08
A Phase 3, Placebo-controlled, Double-blind Study Assessing Rocatinlimab (AMG 451) Monotherapy in Moderate-to-severe AD (ROCKET-Horizon) Ended

2022-501538-44-00 Atopic Dermatitis 5 2023-04-25
A Phase 3, Placebo-controlled, Double-blind Study Assessing Rocatinlimab Monotherapy in Moderate-to-severe AD (ROCKET-Ignite) Ended

2022-501540-15-00 Atopic Dermatitis 5 2023-04-25
A Phase 3, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of intravenous efzofitimod in patients wit… Ended

2023-506039-13-00 pulmonary sarcoidosis 5 2023-04-12
A Study of Peresolimab (LY3462817) in Adults Participants With Moderately-to-Severely Active Rheumatoid Arthritis Ended

2022-501425-20-00 Rheumatoid Arthritis Arthritis Joint Diseases Muscul 4 2023-04-03
A Open-label Study to Evaluate the Efficacy, Safety, Tolerability of HZN-825 in Patients with Diffuse Cutaneous Systemic Sclerosis Ended

2023-509783-23-00 Diffuse Cutaneous Systemic Sclerosis 4 2023-02-24
Thiamine Against Chronic Rheumatoid Arthritis Fatigue Ended

2022-500922-13-00 Rheumatoid Arthritis 10 2023-02-16
A 12-month, randomized, single-blind, placebo-controlled exposure-response study of TCD601 (siplizumab) in new onset type 1 diabetes patient… Ended

2023-506837-31-00 New onset type I diabetes 4 2023-01-27
Quercus ilex and Quercus robur allergen extracts. Determination of in the vivo histamine equivalent prick test units (HEP). Ended

2024-515189-14-00 Allergy to Quercus ilex and Quercus robur 4 2023-01-26
Study to Evaluate Safety, Tolerability and Efficacy in patients with Primary Biliary Cholangitis of Saroglitazar Magnesium-III (EPICS-III). Ended

2024-518718-14-00 Primary Biliary Cholangitis (PBC) 10 2023-01-23
A Study of Tolinapant in Combination with Oral Decitabine/Cedazuridine and Oral Decitabine/Cedazuridine Alone in Subjects with R/R PTCL Ended

2022-500391-62-00 Subjects with relapsed/refractory peripheral T-cell lym 9 2023-01-19
Treatment with Xeljanz in a population of patients with cutaneous T cell lymphoma Ended

2022-500599-79-00 Mycosis Fungoides 4 2023-01-10
A Long term Safety and Efficacy Study of Danicopan as an Add-on Therapy to C5i in Patients with PNH. Ended

2023-504867-18-00 Patients with Paroxysmal Nocturnal Hemoglobinuria 5 2022-12-05
A Phase 3 Study of Telitacicept for the Treatment of Moderately to Severely Active Systemic Lupus Erythematosus Ended

2022-500445-24-00 Moderately to Severely Active Systemic Lupus Erythemato 5 2022-11-30
A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy of Methotrexate as Remission Maintenance Thera… Ended

2022-501058-12-00 Giant cell arteritis 4 2022-11-23